Published Date : Jan 25, 2016
ALBANY, NY, Jan 25, 2016: MarketResearchReports.biz has recently announced the inclusion of a new market research report to its huge database of research studies. The report provides an in-depth reports of the global non-alcoholic steatohepatitis (NASH) market based on a market overview, market drivers and restraints, opportunities and challenges, market trends, product segmentation, geographical segmentation, and the competitive reports of the market. The research report, titled “Global NASH (Non-Alcoholics Steatohepatitis) Market: Trends, Opportunities And Forecasts (2015-2030) (By Region, By Drugs - Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)”, will help industry experts, drug manufacturers, and major players align their market-based strategies with the dominant trends in the market.
Non-alcoholic steatohepatitis (NASH) is a liver inflammation caused due to accumulated fat in the liver. Building up of fat in the liver can be seen in many cases and for most people it does not cause any problem and symptoms. However, in some cases, the accumulated fat start damaging cells in the liver. This condition can get worse and lead to scarring of the liver, resulting in cirrhosis. NASH is similar to liver disorders caused due to heavy and long-time alcohol consumption, but can also occur in non-drinkers.
According to the research study, the global market for non-alcoholic steatohepatitis is projected to exhibit a 25.56% CAGR between 2020 and 2030 owing to the estimated product launches by the end of 2020.
In the last five years, the significant prevalence of liver disorders, coupled with the tremendous rise in obesity, is expected to boost the global NASH market in the forecast period. NASH, at present, is an enormous and untapped market, since it has no FDA-approved therapeutics. The off-label products that are being used by NASH patients include anti-diabetic medications, antioxidants, antihyper lipidemics, and anti-obesity medications. In addition, the increasing number of patients suffering from the condition is another factor propelling the global NASH market throughout the forecast period. On the other hand, the low prescription rates, low treatment seeking rates, and low diagnosis rates are some of the major factors posing significant challenges for the emerging players in the global NASH market.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/504114
Furthermore, the research report presents a detailed reports of the global NASH market on the basis of geography. Among all the regions, in 2014, the U. S. accounted for a massive 50% of the global NASH market owing to the high number of research initiatives conducted for NASH in this region. The primary reason for this growth is the rising incidence of obesity, diabetes, and the increasing number of people suffering from fatty livers. The U.S. has recorded the highest number of cases of NASH as well as other non-alcoholic fatty liver disorders.
The research report further covers the competitive landscape of the global NASH market including the company profile, contact information, financial overview, business strategies, mergers and acquisitions, SWOT reports, and recent developments of major companies. Some of the major players operating in the global NASH market are Novo Nordisk, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead Sciences, and Genfit.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com